» Articles » PMID: 12890693

Release and Interconversion of P2 Receptor Agonists by Human Osteoblast-like Cells

Overview
Journal FASEB J
Specialties Biology
Physiology
Date 2003 Aug 2
PMID 12890693
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Nucleotides, acting as agonists at P2 receptors, are important extracellular signaling molecules in many tissues. In bone they affect both bone-forming osteoblast and bone-resorbing osteoclast cell activity. The presence of nucleotides in the extracellular microenvironment is largely determined by their release from cells and metabolism by ecto-enzymes, both of which have scarcely been studied in bone. We have investigated adenosine 5'-triphosphate (ATP) release from SaOS-2 osteoblastic cells and the activities of cell surface ecto-enzymes on ATP metabolism. ATP, but not LDH, was detected in SaOS-2 cell conditioned medium, suggesting these cells were actively releasing ATP. Introduction of ADP resulted in increased ATP concentrations in the medium, which was found not to be receptor mediated. Nucleotide inhibition and substrate specificity studies revealed an ecto-nucleoside diphosphokinase (ecto-NDPK) was responsible for the ADP-->ATP conversion; PCR and immunocytochemistry confirmed its presence. Analysis of ATP metabolism over time demonstrated overall ATP degradation was increased by inhibiting ecto-NDPK activity; confirming that the combined action of multiple osteoblast-expressed ecto-enzymes affected extracellular nucleotide concentration. The data establish the coexistence of ATP-consuming, and for the first time, ATP-generating activities on the osteoblast cell surface, the discovery of which has significant implications for studies involving P2 receptor subtypes in bone.

Citing Articles

Effect of antiplatelet and anticoagulant medications on implant survival: a long-term retrospective cohort study.

Chatzopoulos G, Wolff L Oral Maxillofac Surg. 2025; 29(1):43.

PMID: 39847193 PMC: 11759461. DOI: 10.1007/s10006-025-01341-7.


Ticagrelor was associated with lower fracture risk than clopidogrel in the dual anti-platelet regimen among patients with acute coronary syndrome treated with percutaneous coronary intervention.

Lui D, Wong C, Ip A, Ng A J Endocrinol Invest. 2023; 47(4):895-902.

PMID: 37776493 PMC: 10965638. DOI: 10.1007/s40618-023-02205-1.


Silencing NTPDase3 activity rehabilitates the osteogenic commitment of post-menopausal stem cell bone progenitors.

Noronha-Matos J, Pinto-Cardoso R, Bessa-Andres C, Magalhaes-Cardoso M, Ferreirinha F, Costa M Stem Cell Res Ther. 2023; 14(1):97.

PMID: 37076930 PMC: 10116749. DOI: 10.1186/s13287-023-03315-6.


Protective Effects of Higher Exposure to Aspirin and/or Clopidogrel on the Occurrence of Hip Fracture among Diabetic Patients: A Retrospective Cohort Study.

Mao J, Lai J, Fu Y, Yip H, Lai Y, Hsu C Biomedicines. 2022; 10(10).

PMID: 36289888 PMC: 9599449. DOI: 10.3390/biomedicines10102626.


Extracellular ATP and its derivatives provide spatiotemporal guidance for bone adaptation to wide spectrum of physical forces.

Dsouza C, Moussa M, Mikolajewicz N, Komarova S Bone Rep. 2022; 17:101608.

PMID: 35992507 PMC: 9385560. DOI: 10.1016/j.bonr.2022.101608.